{"id":"W2336769999","doi":"10.1200/jco.2006.24.18_suppl.17078","title":"Phase I study of OGX-011, a second generation antisense oligonucleotide (ASO) to clusterin, combined with cisplatin and gemcitabine as first-line treatment for patients with stage IIB/IV non-small cell lung cancer (NSCLC)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Achieve Life Sciences (Canada)","funders":"","keywords":"Gemcitabine; Medicine; Cisplatin; Clusterin; Cancer research; Stage (stratigraphy); Oncology; Deoxycytidine; Oligonucleotide; Internal medicine; Chemotherapy; Molecular biology; Apoptosis; Biology; DNA; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006487195,0.0003057577,0.001836943,0.0002054185,0.00007696165,0.00001365979,0.0001058199,0.0002002467,0.0001265395],"category_scores_gemma":[0.0002843977,0.0001896855,0.0001712797,0.0001573546,0.0001357111,0.00008493726,0.00007251799,0.0002671727,0.000001499436],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002258559,"about_ca_system_score_gemma":0.0006914535,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001588565,"about_ca_topic_score_gemma":0.004424043,"domain_scores_codex":[0.9966213,0.0002291738,0.002123779,0.0004108672,0.0002981412,0.0003168019],"domain_scores_gemma":[0.9957469,0.0009319627,0.001766757,0.000307303,0.0008218085,0.0004252533],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1651129,0.06820124,0.7380968,0.0004793051,0.001177918,0.001693823,0.001188137,0.002684847,0.002534258,0.000004546748,0.002084305,0.01674192],"study_design_scores_gemma":[0.2141844,0.3644539,0.4120891,0.0002165956,0.002086265,0.0001074713,0.0002249855,0.00363112,0.000703619,0.00000575842,0.002025364,0.0002714172],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946364,0.00008588713,0.0007552386,0.0008939019,0.000396344,0.002948143,0.0001193283,0.000009487887,0.0001552896],"genre_scores_gemma":[0.9923971,0.00006452408,0.005538357,0.0005774198,0.0005661604,0.0001002404,0.00003613871,0.000051516,0.0006685621],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3260077,"threshold_uncertainty_score":0.7735152,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05611860557962895,"score_gpt":0.4137367067407564,"score_spread":0.3576181011611275,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}